Amicus Therapeutics (FOLD) Tops Q1 EPS by 5c, Misses on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/14/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates
May 1, 2025 7:00 AM EDT1Q 2025 Total Revenue of $125.2M, a 15% Increase Year-over-Year at CER
Expanding Portfolio through In-Licensing of DMX-200 Phase 3 Program for Rare Kidney Disease with Significant Market Potential in the U.S.
Maintaining 2025 Guidance for Galafold, Reflecting Strong Underlying Demand
Updating 2025 Pombiliti + Opfolda Guidance with New Patient Starts Accelerating in 2H
Adjusting 2025 Total Revenue Growth Guidance to 15-22% at CER
Reiterating GAAP Profitability During H2... More
